We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long‐term follow‐up of 64 children with classical infantile‐onset Pompe disease since 2004: A French real‐life observational study.
- Authors
Tardieu, Marine; Cudejko, Céline; Cano, Aline; Hoebeke, Célia; Bernoux, Delphine; Goetz, Violette; Pichard, Samia; Brassier, Anaïs; Schiff, Manuel; Feillet, François; Rollier, Paul; Mention, Karine; Dobbelaere, Dries; Fouilhoux, Alain; Espil‐Taris, Caroline; Eyer, Didier; Huet, Frédéric; Walther‐Louvier, Ulrike; Barth, Magalie; Chevret, Laurent
- Abstract
Background: Classical infantile‐onset Pompe disease (IOPD) is the most severe form of Pompe disease. Enzyme replacement therapy (ERT) has significantly increased survival but only a few studies have reported long‐term outcomes. Methods: We retrospectively analyzed the outcomes of classical IOPD patients diagnosed in France between 2004 and 2020. Results: Sixty‐four patients were identified. At diagnosis (median age 4 months) all patients had cardiomyopathy and most had severe hypotonia (57 of 62 patients, 92%). ERT was initiated in 50 (78%) patients and stopped later due to being ineffective in 10 (21%). Thirty‐seven (58%) patients died during follow‐up, including all untreated and discontinued ERT patients, and 13 additional patients. Mortality was higher during the first 3 years of life and after the age of 12 years. Persistence of cardiomyopathy during follow‐up and/or the presence of heart failure were highly associated with an increased risk of death. In contrast, cross‐reactive immunologic material (CRIM)‐negative status (n = 16, 26%) was unrelated to increased mortality, presumably because immunomodulation protocols prevent the emergence of high antibody titers to ERT. Besides survival, decreased ERT efficacy appeared after the age of 6 years, with a progressive decline in motor and pulmonary functions for most survivors. Conclusions: This study reports the long‐term follow‐up of one of the largest cohorts of classical IOPD patients and demonstrates high long‐term mortality and morbidity rates with a secondary decline in muscular and respiratory functions. This decreased efficacy seems to be multifactorial, highlighting the importance of developing new therapeutic approaches targeting various aspects of pathogenesis.
- Subjects
FRANCE; ENZYME replacement therapy; OCULAR hypotony; ANTIBODY titer; SCIENTIFIC observation; GLYCOGEN storage disease type II
- Publication
European Journal of Neurology, 2023, Vol 30, Issue 9, p2828
- ISSN
1351-5101
- Publication type
Article
- DOI
10.1111/ene.15894